Reading this article and the stated talents and focus of Roche......one has to wonder if CABO might have found a potential partner in near future. I just don't see EXEL getting CABO to market by itself inclusive of all that is required outside of the science itself.Sounds like Roche knows the business and can expedite the process.Pure speculation of course but after reading this article, this sounds more encouraging to EXEL's opportunities......if it doesn't run out of money first.http://seekingalpha.com/article/901801-exelixis-first-partne...Fortunately for Exelixis, GDC-0973 represents Roche's main effort to protect its melanoma franchise. This guarantees an aggressive and efficient development program for the drug. Roche is 6 months behind GSK, but positive results should enable it to retain its presence in melanoma from 2015 onwards. In parallel, GDC-0973 is in several early stage combination trials.Market ignores a major milestone - a buying opportunityExelixis now has a second drug in pivotal studies, in development by a strong and committed partner. Roche's commitment, a large commercial opportunity, favorable deal terms and a high likelihood of clinical success, make GDC-0973 an important asset for Exelixis that is still not reflected in the company's valuation. This creates a buying opportunity, as the market will eventually acknowledge the opportunity as well as the strategic importance of GDC-0973 to Roche.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst